Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Blank

Showing results (251-260 of 279) with videos related to

Pageof 28
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 21, 2021
Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanomaR V Rawson, C Adhikari, C Bierman, et al.
Cancers|July 21, 2019
Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment RegistryAnouk Jochems, Monique K van der Kooij, Marta Fiocco, et al.
European Journal of Cancer (Oxford, England : 1990)|October 5, 2024
Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registryA Özkan, E Kapiteijn, F van den Bos, et al.
Annals of Surgical Oncology|October 6, 2022
Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?Stephanie A Blankenstein, Johannes J Bonenkamp, Maureen J B Aarts, et al.
International Journal of Cancer|October 4, 2021
The unfavorable effects of COVID-19 on Dutch advanced melanoma careOlivier J van Not, Jesper van Breeschoten, Alfonsus J M van den Eertwegh, et al.
Cancer Research Communications|October 30, 2025
Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid TumorsKristoffer Staal Rohrberg, Juanita S Lopez, Mohammed M Milhem, et al.
Nature Medicine|February 9, 2021
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanomaE A Rozeman, E P Hoefsmit, I L M Reijers, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2024
Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanomaRik J Verheijden, Femke H Burgers, Josephine C Janssen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2015
Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic CellsGerty Schreibelt, Kalijn F Bol, Harm Westdorp, et al.
International Journal of Cancer|February 27, 2023
Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanomaIsabella A J van Duin, Sjoerd G Elias, Alfonsus J M van den Eertwegh, et al.
Pageof 28

Showing results (251-260 of 279) with videos related to

Sort By:
Pageof 28
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 21, 2021
Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanomaR V Rawson, C Adhikari, C Bierman, et al.
Cancers|July 21, 2019
Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment RegistryAnouk Jochems, Monique K van der Kooij, Marta Fiocco, et al.
European Journal of Cancer (Oxford, England : 1990)|October 5, 2024
Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registryA Özkan, E Kapiteijn, F van den Bos, et al.
Annals of Surgical Oncology|October 6, 2022
Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?Stephanie A Blankenstein, Johannes J Bonenkamp, Maureen J B Aarts, et al.
International Journal of Cancer|October 4, 2021
The unfavorable effects of COVID-19 on Dutch advanced melanoma careOlivier J van Not, Jesper van Breeschoten, Alfonsus J M van den Eertwegh, et al.
Cancer Research Communications|October 30, 2025
Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid TumorsKristoffer Staal Rohrberg, Juanita S Lopez, Mohammed M Milhem, et al.
Nature Medicine|February 9, 2021
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanomaE A Rozeman, E P Hoefsmit, I L M Reijers, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2024
Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanomaRik J Verheijden, Femke H Burgers, Josephine C Janssen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2015
Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic CellsGerty Schreibelt, Kalijn F Bol, Harm Westdorp, et al.
International Journal of Cancer|February 27, 2023
Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanomaIsabella A J van Duin, Sjoerd G Elias, Alfonsus J M van den Eertwegh, et al.
Pageof 28